CLOSE X
Advertisement

Britain to genetically modify embryos

News

London - The genetic manipulation of human IVF embryos is to start in Britain for the first time, following a licence application by scientists who want to understand why some women suffer miscarriages.

If the research licence is granted by the British government's fertility watchdog, it will be only the second known occasion in the world where the chromosomes of human embryos have been genetically manipulated using a revolutionary gene-editing technique called Crispr/Cas9. When Chinese scientists announced earlier this year that they had genetically altered “spare” human IVF embryos using Crispr/Cas9 for research purposes, there was deep concern among many who thought that they had gone too far.

Tell a friend
The method means that each round of IVF is far more likely to succeed  sparing couples the agony of repeated attempts at having a child.

The American government later imposed a moratorium on federally funded research in the United States.

The researchers behind the UK application emphasised that the GM embryos will be destroyed once the study is completed, with no risk of them being transplanted into women - which is illegal in Britain. There will be no “GM babies” because the project is aimed solely at basic research into the genetics of early human development, the researchers insisted.

But critics of the manipulation of human IVF embryos - even when done for research purposes - have argued that it is a slippery slope to genetically enhanced “designer babies”. The scientists behind the proposed study in the UK said they have no intention of altering the DNA of future generations but accept this may at some point in the future be safe, medically justifiably and ethically acceptable - for instance to avoid inherited disorders or to confer disease resistance on IVF babies.

“We want to understand the genes human embryos need to develop successfully,” said Kathy Niakan of the Francis Crick Institute in London, who has applied to the Human Fertilisation and Embryology Authority (HFEA) for a research licence to use Crispr/Cas9 on spare IVF embryos donated by couples undergoing fertility treatment.

“We are not contemplating altering genes for clinical purposes - we are interested in basic mechanisms of embryonic development. If any of our discoveries suggest ways to improve embryo development after IVF, or to improve implantation frequency, or to prevent miscarriage, these would involve conventional approaches, not the manipulation of genes,” Dr Niakan said.

“There are suggestions that the methods could be used to correct genetic defects, to provide disease resistance, or even to introduce novel traits that are not found in humans.

“However, it is up to society to decide what is acceptable - science will merely inform what may be possible,” she added. Parliament amended the UK's IVF legislation in 2008 to allow genetic manipulation of embryos less than 14 days old, provided it was for research purposes and sanctioned by the HFEA. Under the HFE Act 2008, it remains illegal to create GM embryos for implanting into the womb, or to edit the “germline” DNA of chromosomes passed on to future generations.

“What we are proposing is in keeping with the HFE Act 2008, which is purely for research purposes. We hope to use this technology to improve our understanding of the earliest stages of human development,” Dr Niakan said. “The knowledge we acquire will be very important for understanding how a healthy human embryo develops, and this will inform our understanding of the causes of miscarriage. The knowledge may also improve embryo development after IVF and might provide better clinical treatments for infertility,” she said.

“If we receive a licence, I would hope to start work as soon as possible. However, it is difficult to know how long it will take to carry out the project. In particular, we need to obtain sufficient embryos,” she added.

Professor Robin Lovell-Badge, a senior scientist at the Francis Crick Institute, who took part in a major review of the ethical implications of Crispr/Cas9, the gene-editing technique that allows accurate and efficient engineering of the human genome, said that germ-line gene therapy is not on the agenda, and that Dr Niakan's proposal is purely aimed at understanding why some women suffer repeated miscarriages.

“The ultimate clinical benefits could be improved methods of IVF and better implantation rates in women who have big problems maintaining a pregnancy because there is something wrong with the interaction between the placenta and the uterus,” Professor Lovell-Badge said: “There is no intention at all [to do germline gene therapy]. It is purely a tool for the understanding the basic biology of early human development,” he said.

However, both scientists emphatically denied that the licence application marks the start of a slippery slope to designer babies.

“Absolutely not. I don't believe in the slippery slope anyway, but within the UK we have very clear regulations. If you do any sort of manipulations on an embryo it is no longer a permitted embryo, it cannot be transferred into a woman. It is illegal to do so,” Professor Lovell-Badge said.

Dr Niakan, who moved from the US to the UK to carry out her research, added: “It is not a slippery slope, because the UK has very tight regulation in this area, and it would be illegal to move in that direction... The HFEA has been instrumental in establishing a culture of proper discourse and regulatory oversight. At the moment, I believe the UK is the best place in the world to do this work.”

A spokesman for the HFEA said: “Genome editing of embryos for use in treatment is illegal. It has been permissible in research since 2009, as long as the research project meets the criteria in the legislation and it is done under an HFEA licence. We have recently received an application to use Crispr-Cas9 in one of our licensed research projects, and it will be considered in due course.”

Tell a friend
Advertisement
X